1. Home
  2. IKT vs SSP Comparison

IKT vs SSP Comparison

Compare IKT & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKT
  • SSP
  • Stock Information
  • Founded
  • IKT 2008
  • SSP 1878
  • Country
  • IKT United States
  • SSP United States
  • Employees
  • IKT N/A
  • SSP N/A
  • Industry
  • IKT Biotechnology: Pharmaceutical Preparations
  • SSP Broadcasting
  • Sector
  • IKT Health Care
  • SSP Industrials
  • Exchange
  • IKT Nasdaq
  • SSP Nasdaq
  • Market Cap
  • IKT 159.2M
  • SSP 172.8M
  • IPO Year
  • IKT 2020
  • SSP 1988
  • Fundamental
  • Price
  • IKT $2.27
  • SSP $1.86
  • Analyst Decision
  • IKT Strong Buy
  • SSP Buy
  • Analyst Count
  • IKT 2
  • SSP 2
  • Target Price
  • IKT $6.50
  • SSP $5.75
  • AVG Volume (30 Days)
  • IKT 194.9K
  • SSP 461.9K
  • Earning Date
  • IKT 03-26-2025
  • SSP 02-21-2025
  • Dividend Yield
  • IKT N/A
  • SSP N/A
  • EPS Growth
  • IKT N/A
  • SSP N/A
  • EPS
  • IKT N/A
  • SSP N/A
  • Revenue
  • IKT $1.00
  • SSP $2,397,162,000.00
  • Revenue This Year
  • IKT N/A
  • SSP $10.34
  • Revenue Next Year
  • IKT N/A
  • SSP N/A
  • P/E Ratio
  • IKT N/A
  • SSP N/A
  • Revenue Growth
  • IKT N/A
  • SSP 1.66
  • 52 Week Low
  • IKT $1.12
  • SSP $1.68
  • 52 Week High
  • IKT $4.20
  • SSP $7.69
  • Technical
  • Relative Strength Index (RSI)
  • IKT 38.70
  • SSP 35.97
  • Support Level
  • IKT $1.90
  • SSP $1.87
  • Resistance Level
  • IKT $2.37
  • SSP $2.03
  • Average True Range (ATR)
  • IKT 0.25
  • SSP 0.14
  • MACD
  • IKT -0.07
  • SSP -0.06
  • Stochastic Oscillator
  • IKT 34.91
  • SSP 1.64

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

Share on Social Networks: